On March 28, 2024, bluebird bio, Inc. was sued for violations of the federal securities laws in the United States District Court for the District of Massachusetts on behalf of investors who purchased or otherwise acquired Blue’s common stock between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.